Therefore, while acute and chronic activation of β2-AR by β2-agonists seems to counteract skeletal myopathy in early stages of the disease, long-term and sustained activation of β2-AR aggravates skeletal myopathy in HF, which might be related to β2-AR desensitization and downregulation reducing its anabolic effects. This evidence concerns the gene ADRB2 and skeletal muscle disorder.